DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy.
Fiche publication
Date publication
décembre 2022
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HARLE Alexandre, Pr MERLIN Jean-Louis, Pr GRANDEMANGE Stéphanie, Dr GILSON Pauline, Dr LAMBERT Aurélien
Tous les auteurs :
Dardare J, Witz A, Betz M, Francois A, Meras M, Lamy L, Lambert A, Grandemange S, Husson M, Rouyer M, Demange J, Merlin JL, Harlé A, Gilson P
Lien Pubmed
Résumé
Damage specific DNA binding protein 2 (DDB2) is an UV-indiced DNA damage recognition factor and regulator of cancer development and progression. DDB2 has dual roles in several cancers, either as an oncogene or as a tumor suppressor gene, depending on cancer localization. Here, we investigated the unresolved role of DDB2 in pancreatic ductal adenocarcinoma (PDAC).
Mots clés
biomarker, chemosensitivity, damage specific DNA binding protein 2, epithelial-to-mesenchymal transition, pancreatic ductal adenocarcinoma, prognosis
Référence
Front Oncol. 2022 12 8;12:1052163